Instructions for Ipigrix (Ipidacrine)
Release form:
tab 20 mg: 50 pcs
Description Ipigrix:
White or almost white tablets, round, flat-cylindrical, chamfered.
1 tab.
Ipidacrine hydrochloride monohydrate 21.6 mg,
which corresponds to Ipidacrine hydrochloride content 20 mg
Auxiliary substances:
lactose monohydrate - 65 mg,
potato starch - 12.6 mg,
potato dried starch - 1.4 mg,
calcium stearate - 1 mg.
25 pcs. - packages of box contour (2) - packages of cardboard×.
The pack can be stamped with a sticker to control the first opening.
ATC codes
N07AA Anticholinesterase drugs
Clinical-pharmacological groups / Group affiliation
Cholinesterase inhibitor
Active substance
Ipidacrine hydrochloride
Pharmacotherapy group
Anticholinesterase agent
Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Best before date
Shelf life is 5 years. Do not apply after the expiry date indicated on the package.
Testimony Ipigrix:
- peripheral nervous system diseases (mono- and polyneuropathy,
- polyradiculopathy, myasthenia gravis and myasthenic syndrome of different etiology);
- Diseases of the CNS (bulbar palsy and paresis, recovery period of organic lesions of the CNS accompanied by motor and/or cognitive impairment);
- treatment of bowel atonia.
Method of use, course and dosage:
The drug is used internally. Doses and duration of treatment are determined individually according to the severity of the disease.
For diseases of the peripheral nervous system are used at 20 mg (1 tabb.) 1-3 times/day. The duration of treatment is 1-2 months. If necessary, the course of treatment can be repeated several times with a break between courses of 1-2 months.
In order to prevent myasthenic crises, in the case of severe neuromuscular conductivity disorders, one - two ml (15-30 mg) solution for a v/m and p/k administration containing 15 mg of Ipidacrine in 1 ml is briefly parenterally administered, then the treatment is continued with Ipidacrine in the form of tablets at a dose of 20-40 mg (one - two tab) 5 times/day.
For diseases of the central nervous system are used 20 mg 2-3 times/day. The course of treatment is two to six months. If necessary, the treatment is repeated.
In the treatment of intestinal atonia, 20 mg are used two to three times/day for one to two weeks.
The maximum daily dose is 200 mg.
Elderly patients and patients with liver and/or kidney disorders do not need dose correction.
If the patient has missed the next dose of the drug, the drug should be taken immediately. Do not apply a double dose to compensate for the missed dose. Further, the intake should continue according to the established dosing regime.
Application for kidney disorders
Patients with impaired kidney function do not need a dose correction.
The preparation is contraindicated in the case of mechanical obstruction of the urinary tract.
Use in liver disorders
Patients with liver function disorders do not need dose correction.
Terms of Sale Ipigrix
The drug is prescription.
Application in elderly patients
Elderly patients do not need a dose correction.
Use in children
The drug is contraindicated in children and adolescents under 18 years of age (there is no systematic data on the safety of use).
Nosology Ipigrix (ICD codes)
G12.2
Motor neuron disease
G24
Dystonia (including dyskinesia)
G54
Lesions of the nerve spine and plexus
G58.8
Other refined types of mononeuropathy
G60
Hereditary and idiopathic neuropathy
G61
Inflammatory polyneuropathy
G62.1
Alcoholic polyneuropathy
G62.8
Other refined polyneuropathies (including radiation polyneuropathy)
G63.2
Diabetic polyneuropathy
G70
Myasthenia gravis and other neuromuscular synapses disorders
G73
Neuromuscular synapse and muscle lesions in diseases classified in other headings
K59.8
Other specified functional intestinal disorders
M54.1
Radikulopathy
M79.2
Neuralgia and Neuritis Unspecified
Pharmacological effect Ipigrix:
Ipidacrine is a reversible cholinesterase inhibitor. It directly stimulates the conduction of impulses through nerve fibers, interneuronal and neuromuscular synapses of the peripheral and central nervous system. The pharmacological effect of ipidacrine is based on a combination of two mechanisms of action:
blockade of potassium channels of neuron membrane and muscle cells;
reversible cholinesterase inhibition at synapses.
Ipidacrine enhances the smooth musculature not only of acetylcholine, but also of adrenaline, serotonin, histamine and oxytocin.
It has the following pharmacological effects Ipigrix:
recovery and stimulation of neuromuscular exercise;
Recovery of impulse in the peripheral nervous system after blockage caused by certain factors (e.g. injury, inflammation, local anesthetics, antibiotics, toxins and chloride potassium);
strengthening the contractility and tone of smooth muscles of internal organs;
specific moderate stimulation of the CNS in combination with individual manifestations of sedative action;
memory improvement.
In preclinical studies, Ipidacrine did not have teratogenic, embryotoxic, mutagenic, carcinogenic or immunotoxic effects, nor did it affect the endocrine system.